Australian Government
Repatriation Medical Authority

PORPHYRIA CUTANEA TARDA

RMA ID Number	Reference List for RMA040-4 as at May 2021
30409	Adami J, Gabel H, Lindelof B, et al (2003). Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer, 89(7): 1221-7.
62184	Agarwal R, Peters TJ, Coombes RC, et al (2002). Tamoxifen-related porphyria cutanea tarda. Med Oncol, 19(2): 121-3.
19568	Agency for Toxic Substances and Disease Registry (Sept 1997). Hexachlorobenzene. Retrieved 23 August 2000, from www.atsdr.cdc.gov/tfacts90.html
96819	Aguilera P, Laguno M, To-Figueras J (2016). Human immunodeficiency virus and risk of porphyria cutanea tarda: a possible association examined in a large hospital. Photodermatol Photoimmunol Photomed, 32(2): 93-7.
19435	Al-Awami Y, Sears DA, Carrum G, et al (1997). Pure red cell aplasia associated with hepatitis C infection. Am J Med Sci, 314(2): 113-7.
19559	Albitar S, Bourgeon B, Chuet C (1999). Porphyria cutanea tarda, hepatitis C infection, and iron overload in a patient on hemodialysis. Am J Med, 106(2): 266-7.
62287	Almehmi A, Deliri H, Szego GG, et al (2005). Porphyria cutanea tarda in a patient with HIV-infection. W V Med J, 101(1): 19-21.
19376	Andersen KE, Fischbein A, Kestenbaum D, et al (1977). Plumbism from airborne lead in a firing range. An unusual exposure to a toxic heavy metal. Am J Med, 63(2): 306-12.
63587	Anderson KE (2007). [Comment] Porphyria cutanea tarda: A possible role for ascorbic acid. Hepatology, 45(1): 6-8.
63120	Anderson KE, Kappas A (2010). The Porphyrias. ACP Medicine, vii: 1-12. BC Decker Inc.
96117	Arya SK, Raj A, Kohli P, et al (2019). Total corneal melt in patient with porphyria cutanea tarda in presence of another risk factor. Ocul Immunol Inflamm, 27(4): 610-3.
19789	Ayala F, Santoianni P (1993). Drug-induced cutaneous porphyria. Clin Dermatol, 11(4): 535-9.
96807	Aziz Ibrahim A, Esen UI (2004). Porphyria cutanea tarda in pregnancy: a case report. J Obstet Gynaecol, 24(5): 574-5.
62201	Badenas C, To-Figueras J, Phillips JD, et al (2009). Identification and characterization of novel uroporphyrinogen decarboxylase gene mutations in a large series of porphyria cutanea tarda patients and relatives. Clin Genet, 75(4): 346-53.
96936	Barton JC, Edwards CQ (2016). Porphyria cutanea tarda associated with HFE C282Y homozygosity, iron overload, and use of a contraceptive vaginal ring. J Community Hosp Intern Med Perspect, 6(1): 30380.
19564	Benner VA, Edler L, Mayer K, et al (1994). Untersuchungsprogramm dioxin "der Berufsgenossenschaft der" chemischen industrie. Arbeitsmed Sozialmed Umweltmed, 29: 11-6.

14329	Bertazzi PA, Bernucci I, Brambilla G, et al (1998). The Seveso studies on early and long-term effects of dioxin exposure: a review. Environ Health Perspect, 106(Suppl 2): 625-33.
96810	Bessone F, Poles N, Roma MG (2014). Challenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesis. World J Hepatol, 6(6): 394-409.
19863	Bickers DR, Pathak MA, Lim HW (1993). The Porphyrias. Dermatology in General Medicine, McGraw Hill, New York.
62190	Bilo L, Meo R, Fulvia de Leva M (2006). Levetiractam in idiopathic generalised epilepsy and porphyria cutanea tarda. Clin Drug Investig, 26(6): 357-9.
13439	Blakely KM, Drucker AM, Rosen CF (2019). Drug-induced photosensitivity-An update: Culprit drugs, prevention and management. Drug Saf, 42(7): 827-47.
18901	Blauvelt A (1996). Hepatitis C virus and human immunodeficiency virus infection can alter porphyrin metabolism and lead to porphyria cutanea tarda. Arch Dermatol, 132(12): 1503-4.
19029	Blauvelt A, Harris HR, Hogan DJ, et al (1992). Porphyria cutanea tarda and human immunodeficiency virus infection. Int J Dermatol, 31(7): 474-9.
19860	Bleakley P, Nichol AW, Collins AG (1979). Diazinon and porphyria cutanea tarda. Med J Aust, 1(8): 314-5.
19638	Bleiberg J, Wallen M, Brodkin R, et al (1964). Industrially acquired porphyria. Arch Dermatol, 89: 793-7.
63589	Bohm F, Edge R, Foley S, et al (2001). Antioxidant inhibition of porphyrin-induced cellular phototoxicity. J Photochem Photobiol B, 65(2-3): 177-83.
19028	Boisseau AM, Couzigou P, Forestier JF, et al (1991). Porphyria cutanea tarda associated with Human Immunodeficiency Virus infection: A study of four cases and review of the literature. Dermatologica, 182(3): 155-9.
62185	Bonkovsky HL, Lambrecht RW, Shan Y (2003). Iron as a co-morbid factor in nonhemochromatotic liver disease. Alcohol, 30(2): 137-44.
62762	Breccia M, Latagliata R, Carmosino I, et al (2004). [Comment] Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia. Leukemia, 18(1): 182.
18962	Bulaj ZJ, Phillips JD, Ajioka RS, et al (2000). Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood, 95(5): 1565-71.
62294	Bulat V, Lugovic L, Situm M, et al (2007). Porphyria cutanea tarda as the most common porphyria. Acta Dermatovenerol Croat, 15(4): 254-63.
19608	Burnham TK, Fosnaugh RP (1961). Porphyria, diabetes, and their relationship: a case report. Arch Dermatol, 83: 717-22.
19442	Burns JE, Miller FM, Gomes ED, et al (1974). Hexachlorobenzene exposure from contaminated DCPA in vegetable spraymen. Arch Environ Health, 29(4): 192-4.
13422	Cabanillas M, Peteiro C, Toribio J (2006). Multiple myeloma associated with porphyria cutanea tarda: a possible role of bortezomib. Dermatology, 213(3): 246-7.
19557	Callen JP (1988). Porphyrias. Dermatological Signs of Internal Disease, 206-11. WB Saunders Co. Philadelphia.
18990	Calvert GM, Sweeney MH, Fingerhut MA, et al (1994). Evaluation of Porphyria cutanea tarda in US workers exposed to 2,3,7,8-Tetrachlorodibenzo-p-dioxin. Am J Ind Med, 25(4): 559-71.
19553	Camisa C, Fox M, Quillin A, et al (1995). Coexistence of subacute cutaneous lupus erythematosus and porphyria cutanea tarda: a case report. Cutis, 56(2): 101-3.
98230	Carrieri P, Petracca M, Montella S, et al (2013). Sporadic porphyria cutanea tarda in a patient with multiple sclerosis treated with interferon beta 1-a therapy: a case report. J Clin Neurol, 9(3):196-7.

62297	Cassiman D, Vannoote J, Roelandts R, et al (2008). Porphyria cutanea tarda and liver disease. A retrospective analysis of 17 cases from a single centre and review of the literature. Acta Gastroenterol Belg, 71(2): 237-42.
19610	Castanet J, Lacour J, Bodokh I, et al (1994). Porphyria cutanea tarda in association with human immunodeficiency virus infection: is it related to hepatitis C virus infection? Arch Dermatol, 130(5): 664-5.
96856	Celesia BM, Onorante A, Nunnari G, et al (2007). Porphyria cutanea tarda in an HIV-1-infected patient after the initiation of tipranavir/ritonavir: case report. AIDS, 21(11): 1495-6.
23639	Centers for Disease and Control (1984). Porphyria cutanea tarda and sarcoma in a worker exposed to 2, 3, 7, 8-tetrachlorodibenzodioxin--Missouri. MMWR Morb Mortal Wkly Rep, 33(8): 113-4.
20147	Centre Francais des Porphyries (2000). Internet Site: Retrieved 3 January 2001, from http://perso.wanadoo.fr/porphyries-france/cfp.htm
19438	Chalem P, Ghnassia AM, Nordmann Y, et al (1999). Porphyria cutanea tarda affecting a rheumatoid arthritis patient treated with methotrexate: association or coincidence? Rheumatology (Oxford), 38(5): 453-6.
19556	Chalmers JN, Gillam AE, Kench JE (1940). Porphyrinuria in a case of industrial methylchloride poisoning. Lancet, 236(6122): 806-7.
64100	Chan CC, Lin SJ (2011). Images in clinical medicine: Porphyria Cutanea Tarda. N Engl J Med, 365(12): 1128.
19443	Chan CH (1975). Primary carcinoma of the liver. Med Clin North Am, 59(4): 989-94.
18903	Checketts SR, Morrison KA, Baughman RD (1999). Nonsteroidal anti-inflammatory-induced pseudoporphyria: is there an alternative drug? Cutis, 63(4): 223-5.
96003	Christiansen AL, Aagaard L, Krag A, et al (2016). Cutaneous porphyrias: Causes, symptoms, treatments and the Danish Incidence 1989-2013. Acta Derm Venereol, 96(7): 868-72.
19574	Clemmensen O, Thomsen K (1982). Porphyria cutanea tarda and systemic lupus erythematosus. Arch Dermatol, 118(3): 160-2.
20143	Cohen PR (1991). Porphyria cutanea tarda in human immunodeficiency virus-seropositive men: Case report and literature review. J Acquir Immune Defic Syndr (1988), 4(11): 1112-7.
63590	Cordova KB, Oberg TJ, Malik M, et al (2009). Dermatologic conditions seen in end-stage renal disease. Semin Dial, 22(1): 45-55.
19575	Cram DL, Epstein JH, Tuffanelli DL (1973). Lupus erythematosus and porphyria: coexistence in seven patients. Arch Dermatol, 108(6): 779-84.
62298	Cribier B, Chiaverini C, Dali-Youcef N, et al (2009). Porphyria cutanea tarda, hepatitis C, uroporphyrinogen decarboylase and mutations of HFE gene. A case control study. Dermatology, 218(1): 15-21.
19340	Cripps DJ (1987). Diet and alcohol effects on the manifestation of hepatic porphyrias. Fed Proc, 46(5): 1894-900.
63354	Cripps DJ, Peteres HA, Gocmen A, et al (1984). Porphyria turcica due to hexachlorobenzene: a 20 to 30 year follow-up study on 204 patients. Br J Dermatol, 111(4): 413-22.
62195	Cruz MJ, Alves S, Baudrier T, et al (2010). Porphyria cutanea tarda induced by tamoxifen. Dermatol Online Jl, 16(9): 2.
62300	Cruz-Rojo J, Fontanellas A, Moran-Jimenez MJ, et al (2002). Precipitating/aggravating factors of porphyria cutanea tarda in Spanish patients. Cell Mol Biol (Noisy-le-grand), 48(8): 845-52.
19628	Currier MF, McClimans CD, Barna-Lloyd G (1980). Hexachlorobenzene blood levels and the health status of men employed in the manufacture of chlorinated solvents. J Toxicol Environ Health, 6(2): 367-77.

19662	Dabrowska E, Jablonska-Kaszewska I, Lukiasiak J, et al (2000). Serum iron and copper and their relations to hepatocellular carcinoma in porphyria cutanea tarda and hemochromatosis patients - case report. Biofactors, 11(1-2): 131-4.
97065	D'Alessandro R, Rocchi E, Cristina E, et al (1988). Safety of valproate in porphyria cutanea tarda. Epilepsia, 29(2): 159-62.
19551	Daniell WE, Stockbridge HL, Labbe RF, et al (1997). Environmental chemical exposures and disturbances of heme synthesis. Environ Health Perspect, 105(Suppl 1): 37-53.
96809	Dawe R (2017). An overview of the cutaneous porphyrias. Retrieved 1 July 2020, from https://f1000research.com/articles/6-1906/v1
19266	Day RS, Eales L (1980). Porphyrins in chronic renal failure. Nephron, 26(2): 90-5.
62291	de Geus HR, Dees A (2006). Sporadic porphyria cutanea tarda due to haemochromatosis. Neth J Med, 64(8): 307-9.
19027	de Salamanca RE, Sanchez-Perez J, Diaz-Mora F, et al (1990). [Comment] Porphyria cutanea tarda associated with HIV infection: are those conditions pathogenetically related or merely coincidental? AIDS, 4(9): 926-7.
64084	DeCastro M, Sanchez J, Herrera JF, et al (1993). Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. Hepatology, 17(4): 551-7.
19566	Desnick RJ (1998). The Porphyrias. Harrison's Principles of Internal Medicine, 14th Edition, Vol 2: 2152-8. McGraw-Hill, New York.
63119	Desnick RJ, Batwani M (2012). The porphyrias. Porphyria cutanea tarda (PCT). Harrison's Principles of Internal Medicine, 18th Edition, Chapter 358: 3177-8.
96808	Dogra S, Jindal R (2011). Cutaneous manifestations of common liver diseases. J Clin Exp Hepatol, 1(3): 177-84.
18968	Doss M, Lange CE, Veltman G (1984). Vinyl chloride-induced hepatic coproporphyrinuria with transition to chronic hepatic porphyria. Klin Wochenschr, 62(4): 175-8.
19123	Doss M, Sauer H, von Tiepermann R, et al (1984). Development of chronic hepatic porphyria (porphyria cutanea tarda) with inherited uroporphyrinogen decarboxylase deficiency under exposure to dioxin. Int J Biochem, 16(4): 369-73.
18939	Drobacheff C, Derancourt C, Van Landuyt H (1998). Porphyria cutanea tarda associated with human immunodeficiency virus infection. Eur J Dermatol, 8(7): 492-6.
19562	ECO-USA (2000). Hexachlorobenzene. Internet site: eco-usa.net/toxics/bhc.html
63355	Egger NG, Goeger DE, Payne D, et al (2002). Porphyria cutanea tarda. Multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci, 47(2): 419-26.
19312	Elder GH (1980). The porphyrias: clinical chemistry, diagnosis and methodology. Clin Haematol, 9(2): 371-98.
472	Elmets CA (2019). Pseudoporphyria. Retrieved 14 December 1994, from https://www.uptodate.com/contents/pseudoporphyria
64085	Emamaullee JA, Thiesen A, Owen RJ, et al (2011). Hepatobiliary and pancreatic: Multinodular fatty liver associated with porphyria cutanea tarda. J Gastroenterol Hepatol, 26(1): 211.
18896	English JC, Peake MF, Becker LE (1996). Hepatitis C and porphyria cutanea tarda. Cutis, 57(6): 404-8.
25119	Ergen EN, Seidler E, Parekh S, et al (2013). Is non-alcoholic steatohepatitis a predisposing factor to porphyria cutanea tarda? Photodermatol Photoimmunol Photomed, 29(2): 106-8.
19561	Ewing S, Crosby DL (1997). Renal transplantation for porphyria cutanea tarda. N Engl J Med, 336(11): 811.

19627	Fakan F, Chlumska A, Krijt J, et al (1998). Cytoplasmic liver cell inclusions - a typical feature of porphyria cutanea tarda - are absent in porphyria-related hepatic neoplasias. Neoplasma, 45(2): 102-6.
19550	Falk H, Steenland NK (1998). Vinyl chloride and polyvinyl chloride. Environmental & Occupational Medicine, 3rd Edition, Chapter 93: 1251-9. Lipincott-Raven, Philadelphia.
62187	Fargion S, Fracanzani AL (2003). [Comment] Prevalence of hepatitis C virus infection in porphyria cutanea tarda. J Hepatol, 39(4): 635-8. Comment on ID: 62186.
19030	Fargion S, Piperno A, Cappellini MD, et al (1992). Hepatitis C virus and porphyria cutanea tarda: Evidence of a strong association. Hepatology, 16(6): 1322-6.
63754	Fedeles F, Murphy M, Rothe MJ, et al (2010). Nutrition and bullous skin diseases. Clin Dermatol, 28(6): 627-43.
13383	Filho FB, Santos MV, de Carvalho FN, et al (2012). HAART: A risk factor for development of porphyria cutanea tarda? Rev Soc Bras Med Trop, 45(6): 764-7.
19856	Fitzpatrick JE (1992). New histopathologic findings in drug eruptions. Dermatol Clin, 10(1): 19-36.
64105	Fleming LE (1992). Unusual occupational gastrointestinal and hepatic disorders. Occup Med, 7(3): 433-48.
57743	Fletcher LM, Powell LW (2003). Hemochromatosis and alcoholic liver disease. Alcohol, 30(2): 131-6.
64086	Flueckiger F, Steiner H, Leitinger G, et al (1991). Nodular focal fatty infiltration of the liver in acquired porphyria cutanea tarda. Gastrointest Radiol, 16(3): 237-9.
62197	Fontanellas A, Martinez-Fresno M, Garrido-Astray MC, et al (2010). Smoking but not homozygosity for CYP1A2 g-163A allelic variant leads to earlier disease onset in patients with sporadic porphyria cutanea tarda. Exp Dermatol, 19(8): e326-8.
98232	Franciosi EB, Amano SU, Scharf MJ (2020). Porphyria cutanea tarda associated with nitrofurantoin: A unique drug reaction. Dermatol Ther, 33(6):e14026.
62196	Frank J, Poblete-Gutierrez P (2010). Porphyria cutanea tarda - when skin meets liver. Best Pract Res Clin Gastroenterol, 24(5): 735-45.
19855	Franks AG Jr, Pulini M, Bickers DR, et al (1979). Carbohydrate metabolism in porphyria cutanea tarda. Am J Med Sci, 277(2): 163-71.
60509	Franzon VA, Mikilita ES, Camelo FH, et al (2016). Porphyria cutanea tarda in a HIV- positive patient. An Bras Dermatol, 91(4): 520-3.
20501	Fritsch C, Lang K, von Schmiedeberg S, et al (1998). Porphyria cutanea tarda. Skin Pharmacol Appl Skin Physiol, 11(6): 321-35.
96812	Fritsch S, de Lima Wojcik AS, Schade L, et al (2012). Increased photosensitivity? Case report of porphyria cutanea tarda associated with systemic lupus erythematosus. Rev Bras Reumatol, 52(6): 968-70.
18937	Furata M, Kaito M, Gabazza E, et al (2000). Ineffective interferon treatment of chronic hepatitis C-associated porphyria cutanea tarda, but with a transient decrease in HCV RNA levels. J Gastroenterol, 35(1): 60-2.
13510	Gaida-Hommernick B, Rieck K, Runge U (2001). Oxcarbazepine in focal epilepsy and hepatic porphyria: a case report. Epilepsia, 42(6): 793-5.
63471	Gibson GE, McEvoy MT (1998). Coexistence of lupus erythematosus and porphyria cutanea tarda in fifteen patients. J Am Acad Dermatol, 38(4): 569-73.
19267	Gilchrest B, Rowe JW, Mihm MC (1975). Bullous dermatosis of hemodialysis. Ann Intern Med, 83(4): 480-3.
62186	Gisbert JP, Garcia-Buey L, Pajares JM, et al (2003). Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol, 39(4): 620-7.

63745	Glynne P, Deacon A, Goldsmith D, et al (1999). Bullous dermatoses in end-stage renal failure: porphyria or pseudoporphyria. Am J Kidney Dis, 34(1): 155-60.
19563	Gocmen A, Peters HA, Curtis DJ, et al (1989). Hexachlorobenzene episode in Turkey. Biomed Environ Sci, 2(1): 36-43.
98233	Goerz G, Hammer G (1983). Porphyria cutanea tarda and pregnancy. Dermatologica, 166(6):316-8.
19609	Goldstein JA, Safe S (1989). Mechanism of action and structure-activity relationships for the chlorinated dibenzo-p-dioxins and related compounds. Halogenated biphenyls, terphenyls, naphthalenes, dibenzodioxins and related products. Elsevier Science Publishers.
63588	Gorman N, Zaharia A, Trask HS, et al (2007). Effect of iron and ascorbate on uroporphyria in ascorbate-requiring mice as a model for porphyria cutanea tarda. Hepatology, 45(1): 187-94.
95997	Goulding JM, Purohit G, Borg A, et al (2007). Porphyria cutanea tarda complicating transfusion-dependent myelodysplastic syndrome. Br J Haematol, 136(1): 2.
19268	Griffon-Euvrard S, Thivolet J, Calemard E, et al (1977). [Detection of pseudo-porphyria cutanea tarda in 100 hemodialyzed patients (author's transl).] Dermatologica, 155(4): 193-9 [Article in French].
19450	Grossman ME, Bickers DR, Poh Fitzpatrick MB, et al (1979). Porphyria cutanea tarda: Clinical features and laboratory findings in 40 patients. Am J Med, 67(2): 277-86.
96043	Guha SK, Bandyopadhyay D, Saha A, et al (2016). Human immunodeficiency virus associated sporadic nonfamilial porphyria cutanea tarda. Indian J Dermatol, 61(3): 318-20.
62204	Gunn GB, Anderson KE, Patel AJ, et al (2010). Severe radiation therapy-related soft tissue toxicity in a patient with porphyria cutanea tarda: a literature review. Head Neck, 32(8): 1112-7.
63488	Haendchen L, Jordao JM, Haider O, et al (2011). Porphyria cutanea tarda and systemic lupus erythematosus. An Bras Dermatol, 86(1): 173-5.
19858	Hawk JL (1990). Photosensitivity in the elderly. Br J Dermatol, 122(suppl 35): 29-41.
19295	Herrero C, Ozalla D, Sala M, et al (1999). Urinary porphyrin excretion in a human population highly exposed to hexachlorobenzene. Arch Dermatol, 135(4): 400-4.
19033	Herrero C, Vicente A, Brugera M, et al (1993). Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Lancet, 341(8848): 788-9.
98234	Hift RJ (2011). Porphyria cutanea tarda, iron, inflammation and diabetes mellitus. Br J Dermatol, 165(3):453-4. Comment on ID: 63469.
62286	Hift RJ, Corrigall AV, Hancock V, et al (2002). Porphyria cutanea tarda: the etiological importance of mutations in the HFE gene and viral infection is population-dependent. Cell Mol Biol (Noisy-le-grand), 48(8): 853-9.
62761	Ho AY, Deacon A, Osborne G, et al (2003). [Comment] Precipitation of porphyria cutanea tarda by imatinib mesylate? Br J Haematol, 121(2): 375.
19023	Hope W, Lischwe D, Russell W, et al (1984). Porphyria cutanea tarda and sarcoma in a worker exposed to 2,3,7,8-tetrachlorodibenxodioxin - Missouri. MMWR Morb Mortal Wkly Rep, 33(8): 113-4.
96826	Horner ME, Alikhan A, Tintle S, et al (2013). Cutaneous porphyrias part I: epidemiology, pathogenesis, presentation, diagnosis, and histopathology. Int J Dermatol, 52(12): 1464-80.
19552	Hoxtell E, Manick KP, Fisher I (1976). Coexistence of discoid lupus erythematosus and porphyria cutanea tarda. Cutis, 17(1): 83-6.
17845	Hryhorczuk DO, Wallace WH, Persky V, et al (1998). A morbidity study of former pentachlorophenol-production workers. Environ Health Perspect, 106(7): 401-8.

19589	Huang WS, Liao LY, Wang CS, et al (1999). Hepatocellular carcinoma presenting with acquired porphyria: a case report and review of the literature. Changgeng Yi Xue Za Zhi, 22(1): 111-6.
19857	Hussain I, Hepburn NC, Jones A, et al (1996). The association of hepatitis C viral infection with porphyria cutanea tarda in the Lothian region of Scotland. Clin Exp Dermatol, 21(4): 283-5.
13452	IBM Micromedex (2020). Drugs that cause porphyria cutanea tarda. Retrieved 3 July 2020, from https://www.micromedexsolutions.com/micromedex2/librarian/PFDefaultActionId/evidencexpert.DoIntegratedSearch?navitem=topHome&isToolPage=true
18936	Institute of Medicine (1998). Review of the health effects in Vietnam Veterans of exposure to herbicides. Veterans and Agent Orange: 1998 Update, 11-3 - 11-4; 3-1 - 3-80; 11-39. NAS, Washington, USA. [PREPUBLICATION COPY: Uncorrected Proofs].
18935	Institute of Medicine (1996). .Review of the health effects in Vietnam Veterans of exposure to herbicides. Veterans and Agent Orange: 1996 Update, 11-4 - 11-6. NAS, Washington, USA. [PREPUBLICATION COPY: Uncorrected Proofs].
18934	Institute of Medicine (1994). Health effects of herbicides used in Vietnam. Veterans and Agent Orange, 679-83. National Academy Press: Washington.
63593	Institute of Medicine (2011). Appendix B: Short-term adverse health responses. Veterans and Agent Orange: Update 2010, 639-43. National Academies Press - Washington, DC.
19567	Inter-Organization Programme for the Sound Man Chemicals (IOMC) (1995). Persistent Organic Pollutants Assessments Report, Dec. 1995. An assessment report on: DDT-Aldrin-Dieldrin-Endrin-Chlordane-Heptachlor-Hexachlorobenzene-Mirex-Toxaphene-Polychlorinated biphenyls-Dioxins and Furans. . Retrieved 23 August 2000, from http://www.chem.unep.ch/pops/indxhtms/asses0.html
62205	Jalil S, Grady JJ, Lee C, et al (2010). Associations among behaviour-related susceptibility factors in porphyria cutanea tarda. Clin Gastroenterol Hepatol, 8(3): 297-302.
19314	Jarrell J, Gocmen A, Foster W, et al (1998). Evaluation of reproductive outcomes in women inadvertently exposed to hexachlorobenzene in southeastern Turkey in the 1950s. Reprod Toxicol, 12(4): 469-76.
62760	Jessner W, Der-Petrossian M, Christiansen L, et al (2002). [Comment] Porphyria cutanea tarda during interferon/ribavirin therapy for chronic hepatitis C. Hepatology, 36(5): 1301-2.
95983	Jones RE, Chelsky M (1986). Further discussion concerning porphyria cutanea tarda and TCDD exposure. Arch Environ Health, 41(2): 100-3.
19114	Jung D, Konietzko J, Reill-Konietzko G, et al (1994). Porphyrin studies in TCDD-exposed workers. Arch Toxicol, 68(9): 595-8.
14118	Kalmaz EE, Kalmaz GD (1984). Carcinogenicity and epidemiological profile analysis of vinyl chloride and polyvinyl chloride. Regul Toxicol Pharmacol, 4(1): 13-27.
19573	Keczkes E, Barker DJ (1976). Malignant hepatoma associated with acquired hepatic cutaneous porphyria. Arch Dermatol, 112(1): 78-82.
19296	Kim JJ, Lim HW (1999). Hexachlorobenzene and porphyria cutanea tarda. Arch Dermatol, 135(4): 459-60.
18943	Kimbrough RD (1972). Toxicity of chlorinated hydrocarbons and related compounds: A review including chlorinated dibenzodioxins and chlorinated dibenzofurans. Arch Environ Health, 25(2): 125-31.
19449	Kordac V, Semradova M (1974). Treatment of porphyria cutanea tarda with chloroquine. Br J Dermatol, 90(1): 95-100.

10330	Kotseva K (1996). Five year follow-up study of the incidence of arterial hypertension and coronary heart disease in vinyl chloride monomer and polyvinyl chloride production workers. Int Arch Occup Environ Health, 68(6): 377-9.
96821	Kranzelbinder B, Wiednig M, El-Shabrawi-Caelen L, et al (2015). Sclerodermiform porphyria cutanea tarda after torasemide. Eur J Dermatol, 25(5): 484-5.
62193	Kratka K, Dostalikova-Cimburova M, Michalikova H, et al (2008). High prevalence of HFE gene mutations in patients with porphyria cutanea tarda in the Czech Republic. Br J Dermatol, 159(3): 585-90.
19862	Kuokkanen K (1971). Porphyria cutanea tarda due to colchicine in a patient with gout. Acta Derm Venereol, 51(4): 319-20.
63343	Kushner JP, Steinmuller DP, Lee GR (1975). The role of iron in the pathogenesis of porphyria cutanea tarda. II. Inhibitor of uroporphyrinogen decarboxylase. J Clinl Invest, 56(3): 661-7.
19624	Kutz DC, Bridges AJ (1995). Bullous rash and brown urine in a systemic lupus erythematosus patient treated with hydroxychloroquine. Arthritis Rheum, 38(3): 440-3.
62299	Labidi J (2010). Porphyria cutanea tarda in a chronic hemodialysis patient. Saudi J Kidney Dis Transplant, 21(5): 919-22.
19032	Lacour J, Bodokh I, Castanet J, et al (1993). Porphyria cutanea tarda and antibodies to hepatitis C virus. Br J Dermatol, 128(2): 121-3.
19026	Lafeuillade A, Dhiver C, Martin I, et al (1990). [Comments] Porphyria cutanea tarda associated with HIV infection. AIDS, 4(9): 924-5.
97067	LaPresto L, Nyanda H, Knapp CF, et al (2014). Porphyria cutanea tarda in a child following multi-agent chemotherapy. J Drugs Dermatol, 13(4): 489-91.
1951	Lathrop GD, Wolfe WH, Albanese RA, et al (1984). Project RANCH HAND II. An Epidemiologic Investigation of Health Effects in Air Force Personnel Following Exposure to Herbicides. Baseline Mortality Study Results. Air Force health study, USAF School of Aerospace Medicine, Aerospace Medical Division, Brooks Air Force Base, Texas.
96828	Lee CH, Yuen MM, Chow WS, et al (2012). A man with a blistering eruption and tuberculosis. BMJ, 344: d8351.
96813	Lee KG, Hyun JJ, Seo YS, et al (2010). Liver cirrhosis induced by porphyria cutanea tarda: A case report and review. Gut Liver, 4(4): 551-5.
19439	Lee PK, Abrahams I, Bickers DR (1999). Porphyria cutanea tarda occurring in a patient with renal failure, systemic lupus erythematosus and chronic hepatitis C infection treated with haemodialysis. Cutis, 64(4): 237-9.
19592	Lefkowitch JH, Grossman ME (1983). Hepatic pathology in porphyria cutanea tarda. Liver, 3(1): 19-29.
13463	Leo RJ, Cannuli AR (1996). Porphyria cutanea tarda associated with carbamazepine treatment. Am J Psychiatry, 153(3): 443-4.
20153	Lim HW (1997). Role of viral infection in porphyria cutanea tarda. Photodermatol Photoimmunol Photomed, 13(3): 75-7.
19445	Lim HW, Mascaro JM (1995). The porphyrias and hepatocellular carcinoma. Dermatol Clin, 13(1): 135-42.
20144	Lim HW, Periera A, Sassa S, et al (1998). Early-stage HIV infection and hepatitis C virus infection are associated with elevated serum porphyrin levels. J Am Acad Dermatol, 39(6): 956-9.
96815	Loon JC, Han T, Thet Z (2017). Bullous lesions in a haemodialysis patient. Nephrology (Carlton), 22(10): 822-3.
19649	Loret de Mola JR, Muise KL, Duchon MA (1996). Porphyria cutanea tarda and pregnancy. Obstet Gynecol Surv, 51(8): 493-7.
19650	Lustbader ED, Hann HW, Blumberg BS (1983). Serum ferritin as a predictor of host response to hepatitis B virus infection. Science, 220(4595): 423-5.
19555	Lynch RE, Lee GR, Kushner JP (1975). Porphyria cutanea tarda associated with disinfectant misuse. Arch Intern Med, 135(4): 549-52.

19313	Magnus IA (1980). Cutaneous porphyria. Clin Haematol, 9(2): 273-302.
20145	Mansourati FF, Stone VE, Mayer KH (1999). Porphyria cutanea tarda and HIV/AIDS: a review of pathogenesis, clinical manifestations and management. Int J STD AIDS, 10(1): 51-6.
19558	Marks GS (1985). Exposure to toxic agents: the heme biosynthetic pathway and hemoproteins as indicator. Crit Rev Toxicol, 15(2): 151-79.
62302	Mascaro JM (2003). [Comment] New reasons for an archaic treatment. Phlebotomy in sporadic porphyria cutanea tarda. Arch Dermatol, 139(3): 379-80. Comment on ID: 62301.
13875	Mas-Vidal A, Coto-Segura P, Garcia-Varona A, et al (2010). Porphyria cutanea tarda induced by olmesartan. J Eur Acad Dermatol Venereol, 24(8): 977-8.
18898	McConnell R, Anderson K, Russell W, et al (1993). Angiosarcoma, porphyria cutanea tarda, and probable chloracne in a worker exposed to waste oil contaminated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Br J Ind Med, 50(8): 699-703.
62289	McCrossin I (2002). Porphyria cutanea tarda in south-east New South Wales. Aust J Derm, 45(4): 285-8.
18926	McKenna DB, O'Donnell R, Murphy GM (1997). Porphyria cutanea tarda and hematologic malignancy - a report of 4 cases. Photodermatol Photoimmunol Photomed, 13(4): 143-6.
18902	Mehta S, Lang B (1999). Long-term followup of naproxen-induced pseudoporphyria in juvenile rheumatoid arthritis. Arthritis Rheum, 42(10): 2252-4.
62188	Mendez M, Rossetti MV, Batlle AM, et al (2005). The role of inherited and acquired factors in the development of porphyria cutanea tarda in the Argentinean population. J Am Acad Dermatol, 52(3 Pt 1): 417-24.
19572	Mengistu M (1987). Glucose tolerance and glycosuria in Ethiopian porphyria cutanea tarda patients. Trop Geogr Med, 39(4): 361-5.
19859	Millar JW (1980). Rifampicin-induced porphyria cutanea tarda. Br J Dis Chest, 74(4): 405-8.
62293	Mogl MT, Pascher A, Presser SJ, et al (2007). An unhappy triad: hemochromatosis, porphyria cutanea tarda and hepatocellular carcinoma - a case report. World J Gastroenterol, 13(13): 1998-2001.
19269	Moore MR (1990). An introduction - the history of porphyrins and porphyrias. Mol Aspects Med, 11(1-2): 3-15.
19270	Moore MR, Disler PB (1985). Chemistry and biochemistry of the porphyrins and porphyrias. Clin Dermatol, 3(2): 7-23.
19271	Moore MR, Disler PB (1985). Biochemical diagnosis of the porphyrias. Clin Dermatol, 3(2): 24-40.
18991	Mor Z, Caspi E (1997). Cutaneous complications of hormonal replacement therapy. Clin Dermatol, 15(1): 147-54.
19297	Morton WE (2000). [Comments] Fecal porphyrin measurements are crucial for adequate screening for porphyrinopathy. Arch Dermatol, 136(4): 554-5.
62192	Mosterd K, Henquet C, Frank J (2007). Porphyria cutanea tarda as rare cutaneous manifestation of hepatic metastases treated with interferon. Int J Dermatol, 46(Suppl 3): 19-21.
19569	Mount Sinai School of Medicine (1999). Hazard Database: Chemical teratogens, carcinogens, mutagens - Hexachlorobenzene. Retrieved 23 August 2000, from www.mssm.edu/molbio/hoxpro/hazard/Hexachlorobenzene.html
63690	Mukerji SK, Pimstone NR, Burns M (1984). Dual mechanism of inhibition of rat liver uroporphyrinogen decarboxylase activity by ferrous iron: Its potential role in genesis of porphyria cutanea tarda. Gastroenterology, 87(6): 1248-54.
63469	Munoz-Santos C, Guilabert A, Moreno GN, et al (2011). The association between porphyria cutanea tarda and diabetes mellitus: analysis of a long-term follow-up cohort. Br J Dermatol, 165(3): 486-91.

62203	Munoz-Santos C, Guilabert A, Moreno N, et al (2010). Familial and sporadic porphyria cutanea tarda. Clinical and biochemical features and risk factors in 152 patients. Medicine (Baltimore), 89(2): 69-74.
90277	National Academies of Sciences, Engineering, and Medicine (2018). Veterans and Agent Orange: Update 11. National Academy of Sciences, Washington, D.C. National Academy Press.
18900	Nepveu K, Libman B (1996). [Comment] Hepatitis C as another possible cause of porphyria cutanea tarda and systemic lupus erythematosus: comment on the article by Kutz and Bridges. Arthritis Rheum, 39(2): 352-4.
96816	Nishiyama M, Sakamoto K, Shinagawa Y, et al (2017). A case of porphyria cutanea tarda of the liver exhibiting multifocal macrovesicular steatosis in the background of microvesicular steatosis, probably caused by uneven iron accumulation. Abdom Radiol (NY), 42(7): 1813-8.
19446	Ochai T, Morishima T, Kondo M (1997). Symptomatic porphyria secondary to hepatocellular carcinoma. Br J Dermatol, 136(1): 129-31.
19554	O'Neill T, Simpson J, Smyth SJ, et al (1993). Porphyria cutanea tarda associated with methotrexate therapy. Br J Rheumatol, 32(5): 411-2.
96802	Pallet N, Karras A, Thervet E, et al (2018). Porphyria and kidney diseases. Clin Kidney J, 11(2): 191-7.
94413	Patterson AT, Kaffenberger BH, Keller RA, et al (2016). Skin diseases associated with Agent Orange and other organochlorine exposures. J Am Acad Dermatol, 74(1): 143-70.
13850	Pavanelli GM, Milano SS, Sevignani G, et al (2018). Furosemide-induced pseudoporphyria in a patient with chronic kidney disease: Case report. J Bras Nefrol, 40(3): 287-90.
18961	Pazderova-Vejlupkova J, Nemcova M, Pickova J, et al (1981). The development and prognosis of chronic intoxication by tetrachlordibenzo-p-dioxin in men. Arch Environ Health, 36(1): 5-11.
62376	Peitsch WK, Lorentz K, Goebeler M, et al (2007). Subacute cutaneous lupus erythematosus with bullae associated with porphyria cutanea tarda. J Dtsch Dermatol Ges, 5(3): 220-2.
63689	Percy VA, Naidoo D, Joubert SM, et al (1975). Ascorbate status of patients with porphyria cutanea tarda symptomatica and its effect on porphyrin metabolism. S Afr J Med Sci, 40(4): 185-96.
62191	Phillips JD, Bergonia HA, Reilly CA, et al (2007). A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci U S A, 104(12): 5079-84.
19441	Pimstone NR (1982). Porphyria cutanea tarda. Semin Liver Dis, 2(2): 132-42.
19273	Pimstone NR (1985). Hematologic and hepatic manifestations of the cutaneous porphyrias. Clin Dermatol, 3(2): 83-102.
19265	Piperno A, D'Alba R, Roffi L, et al (1992). Hepatitis C virus infection in patients with idiopathic hemochromatosis (IH) and porphyria cutanea tarda (PCT). Arch Virol Suppl, (4): 215-6.
23983	Plakke MJ, Van Tassel SH, Donato AA (2013). Sun, iron, alcohol and intrinsic liver disease: a recipe for failure. BMJ Case Rep, 2013: bcr2013200158.
62295	Poanta L, Albu A (2007). Chronic hepatitis C with extrahepatic manifestations. Rom J Intern Med, 45(1): 85-8.
19272	Poh-Fitzpatrick MB (1985). Porphyrin-sensitized cutaneous photosensitivity: Pathogenesis and treatment. Clin Dermatol, 3(2): 41-82.
19637	Poh-Fitzpatrick MB (1993). Is porphyria cutanea tarda a paraneoplastic disorder? Clin Dermatol, 11(1): 119-24.
19024	Poland AP, Smith D, Metter G, et al (1971). A health survey of workers in a 2,4-D and 2,4,5-T plant: with special attention to chloracne, porphyria cutanea tarda, and psychological parameters. Arch Environ Health, 22(3): 316-27.
19310	Popper H, Maltoni C, Selikoff IJ (1981). Vinyl chloride-induced hepatic lesions in man and rodents. A comparison. Liver, 1(1): 7-20.

19264	Popper H, Thomas LB (1975). Alterations of liver and spleen among workers exposed to vinyl chloride. Ann N Y Acad Sci, 246: 172-94.
19560	Poux JM, Demontis R, Cadranel JF, et al (1997). Porphyria cutanea tarda in a dialyzed patient with hepatitis C virus infection: dramatic efficacy of small repeated phlebotomies. Am J Med, 103(2): 163-4.
96806	Pyrsopoulos NT, Reddy KR (2001). Extrahepatic manifestations of chronic viral hepatitis. Curr Gastroenterol Rep, 3(1): 71-8.
98816	Rajka G (1984). Pregnancy and porphyria cutanea tarda. Acta Derm Venereol, 64(5):444-5.
62207	Rebora A (2010). Skin diseases associated with hepatitis C virus: facts and controversies. Clin Dermatol, 28(5): 489-96.
98237	Reymann V, Girard C, Dereure O, et al (2017). Sporadic Porphyria in a patient with stage II melanoma treated with interferon a. Curr Drug Saf, 12: 131-3.
19436	Robson KJ, Piette WW (1998). Cutaneous manifestations of systemic diseases. Med Clin North Am, 82(6): 1359-79.
63691	Rocchi E, Casalgrandi G, Masini A, et al (1999). Circulating pro- and antioxidant factors in iron and porphyrin metabolism disorders. Ital J Gastroenterol Hepatol, 31(9): 861-7.
19031	Rocchi E, Gibertini P, Cassanelli M, et al (1986). Hepatitis B virus infection in porphyria cutanea tarda. Liver, 6(3): 153-7.
18942	Roenigk HH, Gottlob ME (1970). Estrogen-induced porphyria cutanea tarda. Arch Dermatol, 102(3): 260-6.
19588	Rook A, Champion RH (1960). Porphyria cutanea tarda and diabetes. Br Med J, 1(5176): 860-1.
62288	Rossmann-Ringdahl I, Olsson R (2005). Porphyria cutanea tarda in a Swedish population: risk factors and complications. Acta Derm Venereol, 85(4): 337-41.
62085	Ruggian JC, Fishbane S, Demento FJ, et al (1996). Porphyria cutanea tarda in a patient on chronic ambulatory peritoneal dialysis. J Am Soc Nephrol, 7(3): 397-402.
96935	Ruox M, Grande C, Durand DV, et al (1996). [Porphyria cutanea tarda and hepatitis B and C virus infection]. Presse Med, 25(33): 1589-91 [Article in French].
22916	Russo JK, Braseth A (2017). Radiation and chemotherapy with no excessive toxicity in a patient with human papillomavirus-related tonsillar cancer and porphyria cutanea tarda: Case report and literature review. Head Neck, 39(10): E102-9.
62199	Ryali ME, Whittier WL (2010). Bullous skin lesions in a patient undergoing chronic hemodialysis. Semin Dial, 23(1): 83-7.
64106	Sabate JM, Bourrier P, Vital JL, et al (2000). Multinodular focal fatty infiltration of the liver in acquired porphyria cutanea tarda. J Hepatol, 33(6): 1022.
19298	Sala M, Sunyer J, Otero R, et al (1999). Health effects of chronic high exposure to hexachlorobenzene in a general population sample. Arch Environ Health, 54(2): 102-9.
13275	Salameh H, Sarairah H, Rizwan M, et al (2018). Relapse of porphyria cutanea tarda after treatment with phlebotomy or 4-aminoquinoline antimalarials: a meta-analysis. Br J Dermatol, 179(6): 1351-7.
18938	Sampietro M, Fiorelli G, Fargion S (1999). Iron overload in porphyria cutanea tarda. Haematologica, 84(3): 248-53.
18967	Sampietro M, Fracanzani AL, Corbetta N, et al (1997). High prevalence of hepatitis C virus type 1b in Italian patients with Porphyria cutanea tarda. Ital J Gastroenterol Hepatol, 29(6): 543-7.
63342	Sampietro M, Piperno A, Lupica L, et al (1998). High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology, 27(1): 181-4.

62285	Sams H, Kiripolsky MG, Bhat L, et al (2004). Porphyria cutanea tarda, hepatitis C, alcoholism, and hemochromatosis: a case report and review of the literature. Cutis, 73(3): 188-90.
62926	Sassa S (2006). Modern diagnosis and management of the porphyrias. Br J Haematol, 135(3): 281-92.
63591	Schaffer M, Schadder PM, Panzer M, et al (2001). Porphyrias associated with malignant tumors: Results of treatment with Ionizing irradiation. Onkologie, 24(2): 170-2.
97074	Scheinfeld N (2006). Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol, 5(3): 228-31.
97066	Schindl A, Trautinger F, Pernerstorfer-Schon H, et al (1998). Porphyria cutanea tarda induced by the use of pravastatin. Arch Dermatol, 134(10): 1305-6.
19299	Selden AI, Floderus Y, Hakan B, et al (1999). Porphyrin status in aluminium foundry workers exposed to hexachlorobenzene and octachlorostyrene. Arch Environ Health, 54(4): 248-53.
19447	Sharara AI (1997). Chronic hepatitis C. South Med J, 90(9): 872-7.
97159	Shehan JM, Huerter CJ (2001). Porphyria cutanea tarda associated with an acute gastrointestinal bleed: the roles of supplemental iron and blood transfusion. Cutis, 68(2): 147-50.
63592	Sinclair PR, Gorman N, Shedlofsky SI, et al (1997). Ascorbic acid deficiency in porphyria cutanea tarda. J Lab Clin Med, 130(2): 197-201.
63743	Sinclair PR, Gorman N, Sinclair JF, et al (1995). Ascorbic acid inhibits chemically induced uroporphyria in ascorbate-requiring rats. Hepatology, 22(2): 565-72.
97049	Singal AK (2019). Porphyria cutanea tarda: Recent update. Mol Genet Metab, 128(3): 271-81.
25014	Singal AK, Anderson KE (2020). Porphyria cutanea tarda and hepatoerythropoietic porphyria: Pathogenesis, clinical manifestations, and diagnosis. Retrieved 21 August 2002, from https://www.uptodate.com/contents/porphyria-cutanea-tarda-and-hepatoerythropoietic-porphyria-pathogenesis-clinical-manifestations-and-diagnosis
96937	Singal AK, Venkata KV, Jampana S, et al (2017). Hepatitis C treatment in patients with porphyria cutanea tarda. Am J Med Sci, 353(6): 523-8.
96814	Singh M, Duckett A, Heincelman M (2019). Porphyria cutanea tarda associated with acute hemorrhagic pancreatitis. J Investig Med High Impact Case Rep, 7: 2324709619852769.
19440	Sinha A, Dixon N, O'Sullivan MM, et al (1999). Porphyria cutanea tarda in a patient with systemic lupus erythematosus. Rheumatology (Oxford), 38(11): 1166-8.
19311	Smith AG, de Matteis F (1980). Drugs and the hepatic porphyrias. Clin Haematol, 92): 399-425.
62292	Sokmen M, Demirsoy H, Ersoy O, et al (2007). Paraneoplastic porphyria cutanea tarda associated with cholangiocarcinoma: case report. Turk J Gastroenterol, 18(3): 201-5.
13263	Spiritos Z, Salvador S, Mosquera D, et al (2019). Acute intermittent porphyria: Current perspectives and case presentation. Ther Clin Risk Manag, 15: 1443-51.
97360	Spiro JM, Demis DJ (1968). The effects of griseofulvin on porphyria cutanea tarda. J Invest Dermatol, 50(3): 202-7.
18940	Stein KM, Raque CJ, Zeigerman JH, et al (1971). Porphyria cutanea tarda induced by natural estrogens: A case report. Obstet Gynecol, 38(5): 755-60.
62301	Stolzel U, Kostler E, Schuppan D, et al (2003). Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria cutanea tarda. Arch Dermatol, 139(3): 309-13.

98238	Strong A, Keller K, Merves J (2020). Early presentation of adult-onset conditions: A dual diagnosis of hereditary hemochromatosis and porphyria cutanea tarda. Mol Genet Metab Rep, 25: 100638.
96811	Sunkara B, Roofeh D, Silver S, et al (2018). The devil's in the dosing: severe drug-induced liver injury in a hydroxychloroquine-naive patient with subacute cutaneous lupus erythematosus and porphyria cutanea tarda. Lupus, 27(8): 1383-8.
62290	Sunyer J, Herrero C, Ozalla D, et al (2002). Serum organochlorines and urinary porphyrin pattern in a population highly exposed to hexachlorobenzene. Environ Health, 1(1): 1.
61957	Szekely E, Bor M, Tasnadi G, et al (2006). Hemorheological status and redox homeostasis of phlebotomised porphyria cutanea tarda patients with diabetes mellitus and in moderate alcohol consumer. Clin Hemorheal Microcirc, 35(3): 387-96.
18941	Tamburro CH (1984). Relationship of vinyl monomers and liver cancers: angiosarcoma and hepatocellular carcinoma. Semin Liver Dis, 4(2): 158-69.
62194	Tarwater K, Misra S, Misra M (2008). Type I (sporadic) porphyria cutanea tarda in a hemodialysis patient: a case report. Hemodial Int, 12(Suppl 2): S38-42.
62189	Thevenot T, Bachmeyer C, Hammi R, et al (2005). Occurrence of porphyria cutanea tarda during peginterferon/ribavirin therapy for chronic viral hepatitis C. J Hepatol, 42(4): 607-8.
19444	Tio TH, Leijnse B, Jarrett A, et al (1957). Acquired porphyria from a liver tumour. Clin Sci (Lond), 16(3): 517-27.
22938	To-Figueras J (2019). Association between hepatitis C virus and porphyria cutanea tarda. Mol Genet Metab, 128(3): 282-7.
19651	Tsukazaki N, Watanabe M, Irifune H (1998). Porphyria cutanea tarda and hepatitis C virus infection. Br J Dermatol, 138(6): 1015-7.
19448	Turnbull A, Baker H, Vernon-Roberts B, et al (1973). Iron metabolism in porphyria cutanea tarda and in erythropoietic protoporphyria. Q J Med, 42(166): 341-55.
19565	University of Queensland, NRCET, Department of Medicine (1999). Porphyria: a patients guide. Retrieved 9 August 2000, from www.uq.edu.au/porphyria/porhhpphtm
18897	Urbanek RW, Cohen DJ (1994). Porphyria cutanea tarda: Pregnancy versus estrogen effect. J Am Acad Dermatol, 31(2 pt 2): 390-2.
64087	Valenti L, Fracanzani AL, Dongiovanni P, et al (2009). Can nonalcoholic steatohepatitis trigger porphyria cutanea tarda clinical manifestations? Intern Emerg Med, 4(1): 91-2.
62997	Van Meter JR, Tierney KR, Pittelkow MR (2011). Iron, genes, and viruses: the porphyria cutanea tarda triple threat. Cutis, 88(2): 73-6.
61589	Vieira FM, Nakhle MC, Abrantes-Lemos CP, et al (2013). Precipitating factors of porphyria cutanea tarda in Brazil with emphasis on hemochromatosis gene (HFE) mutations. Study of 60 patients. An Bras Dermatol, 88(4): 530-40.
64043	Wallace DF, Subramaniam VN (2009). Co-factors in liver disease: The role of HFE-related hereditary hemochromatosis and iron. Biochimi Biophys Acta, 1790(7): 663-70.
19544	Wang JS, Groopman JD (1998). Toxic Liver Disorders. Environmental & Occupational Medicine, 3rd Edition, Chapter 56: 836, 840. Lippincott Williams & Wilkins, Philadelphia.
18944	Webb KB, Ayres SM, Mikes J, et al (1986). The diagnosis of dioxin-associated illness. Am J Prev Med, 2(2): 103-8.
62198	Weber T, Theurich S, Christopeit M, et al (2010). Human herpesvirus-6 as an inducer of porphyria cutanea tarda: implications from a case. Transpl Infect Dis, 12(5): 432-6.
62202	Welsh B (2009). Blistering skin conditions. Aust Fam Physician, 38(7): 484-90.

62206	Wickliffe JK, Abdel-Rahman SZ, Lee C, et al (2011). CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda. Mol Med, 17(3-4): 241-7.
19025	Wissel PS, Sordillo P, Anderson KE, et al (1987). Porphyria cutanea tarda associated with the acquired immune deficiency syndrome. Am J Hematol, 25(1): 107-13.
62200	Wollina U, Kostler E, Koch A, et al (2009). Does chloroquine therapy of porphyria cutanea tarda influence liver pathology? Int J Dermatol, 48(11): 1250-3.
96245	Yang XM, Zhang Y, Wang T, et al (2017). Sporadic porphyria cutanea tarda induced by alcohol abuse. Chin Med J (Engl), 130(16): 2011-2.
62296	Young LC (2007). Porphyria cutanea tarda associated with Cys282Tyr mutation in HFE gene in hereditary hemochromatosis: a case report and review of the literature. Cutis, 80(5): 415-8.
81590	Younossi Z, Park H, Henry L, et al (2016). Extrahepatic manifestations of Hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology, 150(7): 1599-608.